-
1
-
-
0013942402
-
Different ages of onset in varieties of phobias
-
Marks IM, Gelder MG. Different ages of onset in varieties of phobias. Am. J. Psychiatry 123(2), 218-221 (1966).
-
(1966)
Am. J. Psychiatry
, vol.123
, Issue.2
, pp. 218-221
-
-
Marks, I.M.1
Gelder, M.G.2
-
2
-
-
0004235298
-
-
American Psychiatric Association, American Psychiatric Press, Washington, DC, USA
-
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press, Washington, DC, USA (1980).
-
(1980)
Diagnostic and Statistical Manual of Mental Disorders
-
-
-
3
-
-
20344374645
-
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication
-
Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 617-627 (2005).
-
(2005)
Arch. Gen. Psychiatry
, vol.62
, Issue.6
, pp. 617-627
-
-
Kessler, R.C.1
Chiu, W.T.2
Demler, O.3
Merikangas, K.R.4
Walters, E.E.5
-
4
-
-
0035178428
-
Impact of generalized social anxiety disorder in managed care
-
Katzelnick DJ, Kobak KA, DeLeire T et al. Impact of generalized social anxiety disorder in managed care. Am. J. Psychiatry 158(12), 1999-2007 (2001).
-
(2001)
Am. J. Psychiatry
, vol.158
, Issue.12
, pp. 1999-2007
-
-
Katzelnick, D.J.1
Kobak, K.A.2
DeLeire, T.3
-
5
-
-
0029852396
-
The impact of social phobia on quality of life. International Clinical
-
Wittchen H, Beloch E. The impact of social phobia on quality of life. International Clinical Int. Clin. Psychopharmacol. 11(Suppl. 3), 15-23 (1996).
-
(1996)
Int. Clin. Psychopharmacol
, vol.11
, Issue.SUPPL. 3
, pp. 15-23
-
-
Wittchen, H.1
Beloch, E.2
-
6
-
-
20344385026
-
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication
-
Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 593-602 (2005).
-
(2005)
Arch. Gen. Psychiatry
, vol.62
, Issue.6
, pp. 593-602
-
-
Kessler, R.C.1
Berglund, P.2
Demler, O.3
-
7
-
-
39549099619
-
Paroxetine in social anxiety disorder: A remission analysis
-
Presented at:, Barcelona, Spain, 5-9 October
-
Stein DJ, Hunter B, Rolfe T. Paroxetine in social anxiety disorder: a remission analysis. Presented at: 15th ECNP Congress. Barcelona, Spain, 5-9 October 2002.
-
(2002)
15th ECNP Congress
-
-
Stein, D.J.1
Hunter, B.2
Rolfe, T.3
-
8
-
-
0031984593
-
A direct-interview family study of generalized social phobia
-
Stein MB, Chartier MJ, Hazen AL et al. A direct-interview family study of generalized social phobia. Am. J. Psychiatry 155(1), 90-97 (1998).
-
(1998)
Am. J. Psychiatry
, vol.155
, Issue.1
, pp. 90-97
-
-
Stein, M.B.1
Chartier, M.J.2
Hazen, A.L.3
-
9
-
-
0033855524
-
Social phobia in a population-based female adolescent twin sample: Co-morbidity and associated suicide-related symptoms
-
Nelson EC, Grant JD, Bucholz KK et al. Social phobia in a population-based female adolescent twin sample: co-morbidity and associated suicide-related symptoms. Psychol. Med. 30(4), 797-804 (2000).
-
(2000)
Psychol. Med
, vol.30
, Issue.4
, pp. 797-804
-
-
Nelson, E.C.1
Grant, J.D.2
Bucholz, K.K.3
-
10
-
-
0001178316
-
Cognitive-behavioral and pharmacological treatments of social phobia
-
Gould RA, Buckminister S, Pollack MH, Otto MW, Yap L. Cognitive-behavioral and pharmacological treatments of social phobia. Clin. Psychol. Sci. Prac. 4(4), 291-306 (1997).
-
(1997)
Clin. Psychol. Sci. Prac
, vol.4
, Issue.4
, pp. 291-306
-
-
Gould, R.A.1
Buckminister, S.2
Pollack, M.H.3
Otto, M.W.4
Yap, L.5
-
11
-
-
0035010604
-
Psychological and pharmacological treatments of social phobia
-
Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia. J. Clin. Psychopharmacol. 21(3), 311-324 (2001).
-
(2001)
J. Clin. Psychopharmacol
, vol.21
, Issue.3
, pp. 311-324
-
-
Fedoroff, I.C.1
Taylor, S.2
-
12
-
-
0031735121
-
-
Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry 59(Suppl. 17), 54-60 (1998). • Although dated, this is still the only published clinical guideline devoted exclusively to the treatment of social anxiety disorder (SAD) with pharmacotherapy. Describes the epidemiology of SAD, associated comorbidity and the burdens imposed by this disorder. Each section contains recommendations for future research, many of which are still pertinent today.
-
Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry 59(Suppl. 17), 54-60 (1998). • Although dated, this is still the only published clinical guideline devoted exclusively to the treatment of social anxiety disorder (SAD) with pharmacotherapy. Describes the epidemiology of SAD, associated comorbidity and the burdens imposed by this disorder. Each section contains recommendations for future research, many of which are still pertinent today.
-
-
-
-
13
-
-
0038810202
-
WFSBP task force on treatment guidelines for anxiety O-CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders
-
Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. WFSBP task force on treatment guidelines for anxiety O-CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psychiatry 3(4), 171-199 (2002).
-
(2002)
World J. Biol. Psychiatry
, vol.3
, Issue.4
, pp. 171-199
-
-
Bandelow, B.1
Zohar, J.2
Hollander, E.3
Kasper, S.4
Moller, H.J.5
-
14
-
-
0036249434
-
Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy
-
Furmark T, Tillfors M, Marteinsdottir I et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch. Gen. Psychiatry 59(5), 425-433 (2002).
-
(2002)
Arch. Gen. Psychiatry
, vol.59
, Issue.5
, pp. 425-433
-
-
Furmark, T.1
Tillfors, M.2
Marteinsdottir, I.3
-
15
-
-
0015856823
-
A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety
-
Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 32(3), 237-254 (1973).
-
(1973)
Psychopharmacologia
, vol.32
, Issue.3
, pp. 237-254
-
-
Tyrer, P.1
Candy, J.2
Kelly, D.3
-
16
-
-
0023281158
-
Drug treatment of social phobia
-
Gorman JM, Gorman LK. Drug treatment of social phobia. J. Affect. Disord. 13(2), 183-192 (1987).
-
(1987)
J. Affect. Disord
, vol.13
, Issue.2
, pp. 183-192
-
-
Gorman, J.M.1
Gorman, L.K.2
-
17
-
-
0026640346
-
Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine
-
Versiani M, Nardi AE, Mundim FD et al. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br. J. Psychiatry 161, 353-360 (1992).
-
(1992)
Br. J. Psychiatry
, vol.161
, pp. 353-360
-
-
Versiani, M.1
Nardi, A.E.2
Mundim, F.D.3
-
18
-
-
0025720131
-
Long-term treatment of social phobia with clonazepam
-
Davidson JR, Ford SM, Smith RD, Potts NL. Long-term treatment of social phobia with clonazepam. J. Clin. Psychiatry 52(Suppl. 1), 16-20 (1991).
-
(1991)
J. Clin. Psychiatry
, vol.52
, Issue.SUPPL. 1
, pp. 16-20
-
-
Davidson, J.R.1
Ford, S.M.2
Smith, R.D.3
Potts, N.L.4
-
19
-
-
0033736350
-
The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials
-
van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int. Clin. Psychopharmacol. 15 (Suppl. 2), 15-24 (2000).
-
(2000)
Int. Clin. Psychopharmacol
, vol.15
, Issue.SUPPL. 2
, pp. 15-24
-
-
van der Linden, G.J.1
Stein, D.J.2
van Balkom, A.J.3
-
20
-
-
0026826649
-
Psychopharmacological treatment of social phobia: Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
-
van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur. Neuropsychopharmacol. 2(1), 21-29 (1992).
-
(1992)
Eur. Neuropsychopharmacol
, vol.2
, Issue.1
, pp. 21-29
-
-
van Vliet, I.M.1
den Boer, J.A.2
Westenberg, H.G.3
-
21
-
-
0036902244
-
Efficacy of olanzapine in social anxiety disorder: A pilot study
-
Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. J. Psychopharmacol. (Oxford) 16(4), 365-368 (2002).
-
(2002)
J. Psychopharmacol. (Oxford)
, vol.16
, Issue.4
, pp. 365-368
-
-
Barnett, S.D.1
Kramer, M.L.2
Casat, C.D.3
Connor, K.M.4
Davidson, J.R.5
-
22
-
-
0036182223
-
Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials
-
Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J. Clin. Psychiatry 63(2), 152-155 (2002).
-
(2002)
J. Clin. Psychiatry
, vol.63
, Issue.2
, pp. 152-155
-
-
Stein, D.J.1
Stein, M.B.2
Pitts, C.D.3
Kumar, R.4
Hunter, B.5
-
23
-
-
0021798707
-
Social phobia. Review of a neglected anxiety disorder
-
Liebowitz MR, Gorman JM, Fyer AJ, Klein DF. Social phobia. Review of a neglected anxiety disorder. Arch. Gen. Psychiatry 42(7), 729-736 (1985).
-
(1985)
Arch. Gen. Psychiatry
, vol.42
, Issue.7
, pp. 729-736
-
-
Liebowitz, M.R.1
Gorman, J.M.2
Fyer, A.J.3
Klein, D.F.4
-
24
-
-
0031792868
-
Pharmacotherapy of social anxiety disorder
-
Davidson JR. Pharmacotherapy of social anxiety disorder. J. Clin. Psychiatry 59(Suppl. 17), 47-51 (1998).
-
(1998)
J. Clin. Psychiatry
, vol.59
, Issue.SUPPL. 17
, pp. 47-51
-
-
Davidson, J.R.1
-
26
-
-
33845807475
-
The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: A metaanalysis of double-blind, placebo-controlled trials
-
Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a metaanalysis of double-blind, placebo-controlled trials. J. Psychopharmacol. (Oxford) 21(1), 102-111 (2007).
-
(2007)
J. Psychopharmacol. (Oxford)
, vol.21
, Issue.1
, pp. 102-111
-
-
Hedges, D.W.1
Brown, B.L.2
Shwalb, D.A.3
Godfrey, K.4
Larcher, A.M.5
-
27
-
-
0042472877
-
Pharmalogical treatment of social anxiety disorder: A meta-analysis
-
Blanco C, Schneier FR, Schmidt A et al. Pharmalogical treatment of social anxiety disorder: a meta-analysis. Depress. Anxiety 18, 29-40 (2003).
-
(2003)
Depress. Anxiety
, vol.18
, pp. 29-40
-
-
Blanco, C.1
Schneier, F.R.2
Schmidt, A.3
-
28
-
-
85100415918
-
-
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Updated September 2006. John Wiley & Sons Ltd, Chichester, UK (2006).
-
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Updated September 2006. John Wiley & Sons Ltd, Chichester, UK (2006).
-
-
-
-
29
-
-
0036203445
-
Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed
-
Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int. J. Epidemiol. 31(1), 150-153 (2002).
-
(2002)
Int. J. Epidemiol
, vol.31
, Issue.1
, pp. 150-153
-
-
Robinson, K.A.1
Dickersin, K.2
-
30
-
-
39549107015
-
-
World Health Organisation. The ICD-9 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organisation (Ed.), Geneva, Switzerland (1975).
-
World Health Organisation. The ICD-9 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organisation (Ed.), Geneva, Switzerland (1975).
-
-
-
-
33
-
-
0032956810
-
Psychometric properties of the Liebowitz Social Anxiety Scale
-
Heimberg RG, Horner KJ, Juster HR et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol. Med. 29(1), 199-212 (1999).
-
(1999)
Psychol. Med
, vol.29
, Issue.1
, pp. 199-212
-
-
Heimberg, R.G.1
Horner, K.J.2
Juster, H.R.3
-
35
-
-
0018425438
-
A new depression scale designed to be sensitive to change
-
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979).
-
(1979)
Br. J. Psychiatry
, vol.134
, pp. 382-389
-
-
Montgomery, S.A.1
Asberg, M.2
-
37
-
-
0034750007
-
Development of a quality assessment instrument for trials of treatments for depression and neurosis
-
Moncrieff J, Churchill R, Drummond DC, McGuire H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. Int. J. Methods Psychiatr. Res. 10(3), 126-133 (2001).
-
(2001)
Int. J. Methods Psychiatr. Res
, vol.10
, Issue.3
, pp. 126-133
-
-
Moncrieff, J.1
Churchill, R.2
Drummond, D.C.3
McGuire, H.4
-
39
-
-
0030800198
-
Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study
-
Lott M, Greist JH, Jefferson JW et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J. Clin. Psychopharmacol. 17(4), 255-260 (1997).
-
(1997)
J. Clin. Psychopharmacol
, vol.17
, Issue.4
, pp. 255-260
-
-
Lott, M.1
Greist, J.H.2
Jefferson, J.W.3
-
40
-
-
0033874888
-
Publication and related biases
-
Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol. Assess. 4, 1-115 (2000).
-
(2000)
Health Technol. Assess
, vol.4
, pp. 1-115
-
-
Song, F.1
Eastwood, A.J.2
Gilbody, S.3
Duley, L.4
Sutton, A.J.5
-
41
-
-
0002487281
-
Publication bias
-
Russell Sage Foundation, NY, USA
-
Begg C, Cooper H, Hedges L. Publication bias. In: The Handbook of Research Synthesis. Russell Sage Foundation, NY, USA, 339-356 (1994).
-
(1994)
The Handbook of Research Synthesis
, pp. 339-356
-
-
Begg, C.1
Cooper, H.2
Hedges, L.3
-
42
-
-
39549120547
-
-
Deeks J, Higgins J, Altman D. Cochrane Reviewers' Handbook 4.2.5. Updated May 2005. The Cochrane Library (2005).
-
Deeks J, Higgins J, Altman D. Cochrane Reviewers' Handbook 4.2.5. Updated May 2005. The Cochrane Library (2005).
-
-
-
-
43
-
-
0041876133
-
Measuring inconsistency in meta-analyses
-
Higgins JT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br. Med. J. 327(6), 557-560 (2003).
-
(2003)
Br. Med. J
, vol.327
, Issue.6
, pp. 557-560
-
-
Higgins, J.T.1
Thompson, S.G.2
Deeks, J.J.3
Altman, D.G.4
-
44
-
-
84948773232
-
Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis
-
Edition. BMJ, London, UK 2001
-
nd Edition. BMJ, London, UK (2001).
-
nd
-
-
Deeks, J.J.1
Altman, D.G.2
Bradburn, M.J.3
-
45
-
-
0043198131
-
Association of funding and conclusions in randomized drug trials - a reflection of treatment effect or adverse events?
-
Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials - a reflection of treatment effect or adverse events? J. Am. Med. Assoc. 290, 921-928 (2003).
-
(2003)
J. Am. Med. Assoc
, vol.290
, pp. 921-928
-
-
Als-Nielsen, B.1
Chen, W.2
Gluud, C.3
Kjaergard, L.L.4
-
46
-
-
0346366732
-
Quantitative analysis of sponsorship bias in economic studies of antidepressants
-
Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br. J. Psychiatry 183, 498-506 (2003).
-
(2003)
Br. J. Psychiatry
, vol.183
, pp. 498-506
-
-
Baker, C.B.1
Johnsrud, M.T.2
Crismon, M.L.3
Rosenheck, R.A.4
Woods, S.W.5
-
47
-
-
0032789136
-
Treatment of social phobia with gabapentin: A placebo-controlled study
-
Pande AC, Davidson JR, Jefferson JW et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol. 19(4), 341-348 (1999).
-
(1999)
J. Clin. Psychopharmacol
, vol.19
, Issue.4
, pp. 341-348
-
-
Pande, A.C.1
Davidson, J.R.2
Jefferson, J.W.3
-
48
-
-
0034946458
-
Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia
-
Blomhoff S, Haug TT, Hellstrom K et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br. J. Psychiatry 179, 23-30 (2001).
-
(2001)
Br. J. Psychiatry
, vol.179
, pp. 23-30
-
-
Blomhoff, S.1
Haug, T.T.2
Hellstrom, K.3
-
49
-
-
0029094582
-
Sertraline for social phobia: A double-blind, placebo-controlled crossover study
-
Katzelnick DJ, Kobak KA, Greist JH et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am. J. Psychiatry 152(9), 1368-1371 (1995).
-
(1995)
Am. J. Psychiatry
, vol.152
, Issue.9
, pp. 1368-1371
-
-
Katzelnick, D.J.1
Kobak, K.A.2
Greist, J.H.3
-
50
-
-
33847609653
-
Nefazodone in the treatment of generalized social phobia: A randomized, placebo-controlled trial
-
Van Ameringen M, Mancini C, Oakman J et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J. Clin. Psychiatry 68(2), 288-295 (2007).
-
(2007)
J. Clin. Psychiatry
, vol.68
, Issue.2
, pp. 288-295
-
-
Van Ameringen, M.1
Mancini, C.2
Oakman, J.3
-
51
-
-
27944497365
-
Mirtazapine treatment of social phobia in women: A randomized, double-blind, placebo-controlled study
-
Muehlbacher M, Nickel MK, Nickel C et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 25(6), 580-583 (2005).
-
(2005)
J. Clin. Psychopharmacol
, vol.25
, Issue.6
, pp. 580-583
-
-
Muehlbacher, M.1
Nickel, M.K.2
Nickel, C.3
-
52
-
-
22444442937
-
-
Furmark T, Appel L, Michelgard A et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 58(2), 132-142 (2005). •• A novel brain imaging study in which the participants with SAD engaged in public speaking prior to and following 6 weeks of treatment with the Neurokinin-1 receptor antagonist GR205171, citalopram and placebo. Hypothesized reductions in blood flow in the medial temporal lobe (including the hippocampus and amygdala) were observed in both treatment groups, and were associated with large reductions in anxiety and treatment response on the Clinical Global Impressions Improvement scale.
-
Furmark T, Appel L, Michelgard A et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 58(2), 132-142 (2005). •• A novel brain imaging study in which the participants with SAD engaged in public speaking prior to and following 6 weeks of treatment with the Neurokinin-1 receptor antagonist GR205171, citalopram and placebo. Hypothesized reductions in blood flow in the medial temporal lobe (including the hippocampus and amygdala) were observed in both treatment groups, and were associated with large reductions in anxiety and treatment response on the Clinical Global Impressions Improvement scale.
-
-
-
-
53
-
-
0025757170
-
The assessment and treatment of performance anxiety in musicians
-
Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am. J. Psychiatry 148(5), 598-605 (1991).
-
(1991)
Am. J. Psychiatry
, vol.148
, Issue.5
, pp. 598-605
-
-
Clark, D.B.1
Agras, W.S.2
-
54
-
-
0028334924
-
Social phobia: A comparison of behaviour therapy and atenolol
-
Turner S, Beidel DC, Jacob RG. Social phobia: a comparison of behaviour therapy and atenolol. J. Consult. Clin. Psychol. 62(2), 350-358 (1994).
-
(1994)
J. Consult. Clin. Psychol
, vol.62
, Issue.2
, pp. 350-358
-
-
Turner, S.1
Beidel, D.C.2
Jacob, R.G.3
-
55
-
-
0026516493
-
Phenelzine vs atenolol in social phobia: A placebo-controlled comparison
-
Liebowitz MR, Schneier F, Campeas R et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch. Gen. Psychiatry 49(4), 290-300 (1992).
-
(1992)
Arch. Gen. Psychiatry
, vol.49
, Issue.4
, pp. 290-300
-
-
Liebowitz, M.R.1
Schneier, F.2
Campeas, R.3
-
56
-
-
4444333450
-
Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine
-
Allgulander C, Mangano R, Zhang J et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum. Psychopharmacol. 19(6), 387-396 (2004).
-
(2004)
Hum. Psychopharmacol
, vol.19
, Issue.6
, pp. 387-396
-
-
Allgulander, C.1
Mangano, R.2
Zhang, J.3
-
57
-
-
14644404240
-
-
Liebowitz MR, Mangano RM, Bradwejn J, Asnis G, Group SADS. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 66(2), 238-247 (2005).
-
Liebowitz MR, Mangano RM, Bradwejn J, Asnis G, Group SADS. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 66(2), 238-247 (2005).
-
-
-
-
58
-
-
3543043767
-
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study
-
Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety 19(4), 241-248 (2004).
-
(2004)
Depress. Anxiety
, vol.19
, Issue.4
, pp. 241-248
-
-
Lader, M.1
Stender, K.2
Burger, V.3
Nil, R.4
-
59
-
-
12344249711
-
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial
-
Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl.) 177(3), 280-288 (2005).
-
(2005)
Psychopharmacology (Berl.)
, vol.177
, Issue.3
, pp. 280-288
-
-
Stein, M.B.1
Pollack, M.H.2
Bystritsky, A.3
Kelsey, J.E.4
Mangano, R.M.5
-
60
-
-
0031736386
-
Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome
-
Heimberg RG, Liebowitz MR, Hope DA et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch. Gen. Psychiatry 55(12), 1133-1141 (1998).
-
(1998)
Arch. Gen. Psychiatry
, vol.55
, Issue.12
, pp. 1133-1141
-
-
Heimberg, R.G.1
Liebowitz, M.R.2
Hope, D.A.3
-
61
-
-
0028785771
-
Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study
-
Fahlen T, Nilsson H, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr. Scand. 92(5), 351-358 (1995).
-
(1995)
Acta Psychiatr. Scand
, vol.92
, Issue.5
, pp. 351-358
-
-
Fahlen, T.1
Nilsson, H.2
Borg, K.3
Humble, M.4
Pauli, U.5
-
62
-
-
8244233845
-
Moclobemide in social phobia. A double-blind, placebo-controlled clinical study
-
Katschnig K, Stein MB, Buller R. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur. Arch. Psychiatry Clin. Neurosci. 247(2), 71-80 (1997).
-
(1997)
Eur. Arch. Psychiatry Clin. Neurosci
, vol.247
, Issue.2
, pp. 71-80
-
-
Katschnig, K.1
Stein, M.B.2
Buller, R.3
-
63
-
-
0343683384
-
Moclobemide in social phobia: A controlled dose response trial
-
Noyes R Jr, Moroz G, Davidson JR et al. Moclobemide in social phobia: a controlled dose response trial. J. Clin. Psychopharmacol. 17(4), 247-254 (1997).
-
(1997)
J. Clin. Psychopharmacol
, vol.17
, Issue.4
, pp. 247-254
-
-
Noyes Jr, R.1
Moroz, G.2
Davidson, J.R.3
-
64
-
-
0008012999
-
Cognitive therapy versus moclobemide in social phobia: A controlled study
-
Oosterbaan DB, van Balkom AJLM, Spinhoven P, van Oppen P, van Dyck R. Cognitive therapy versus moclobemide in social phobia: a controlled study. Clin. Psychol. Psychother. 8, 263-273 (2001).
-
(2001)
Clin. Psychol. Psychother
, vol.8
, pp. 263-273
-
-
Oosterbaan, D.B.1
van Balkom, A.J.L.M.2
Spinhoven, P.3
van Oppen, P.4
van Dyck, R.5
-
65
-
-
0031912874
-
Placebo-controlled trial of moclobemide in social phobia
-
Schneier FR, Goetz D, Campeas R et al. Placebo-controlled trial of moclobemide in social phobia. Br. J. Psychiatry 172, 70-77 (1998).
-
(1998)
Br. J. Psychiatry
, vol.172
, pp. 70-77
-
-
Schneier, F.R.1
Goetz, D.2
Campeas, R.3
-
66
-
-
0035985962
-
Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder
-
Stein DJ, Cameron A, Amrein R, Montgomery SA. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int. Clin. Psychopharmacol. 17(4), 161-170 (2002).
-
(2002)
Int. Clin. Psychopharmacol
, vol.17
, Issue.4
, pp. 161-170
-
-
Stein, D.J.1
Cameron, A.2
Amrein, R.3
Montgomery, S.A.4
-
67
-
-
14844291585
-
Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study
-
Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br. J. Psychiatry 186, 222-226 (2005).
-
(2005)
Br. J. Psychiatry
, vol.186
, pp. 222-226
-
-
Kasper, S.1
Stein, D.J.2
Loft, H.3
Nil, R.4
-
68
-
-
5044229135
-
Fluoxetine, comprehensive cogntive behavioral therapy, and placebo in generalised social phobia
-
Davidson JRT, Foa EB, Huppert JD et al. Fluoxetine, comprehensive cogntive behavioral therapy, and placebo in generalised social phobia. Arch. Gen. Psychiatry 61, 1005-1013 (2004).
-
(2004)
Arch. Gen. Psychiatry
, vol.61
, pp. 1005-1013
-
-
Davidson, J.R.T.1
Foa, E.B.2
Huppert, J.D.3
-
69
-
-
0036113828
-
Fluoxetine in social phobia: A double-blind, placebo-controlled pilot study
-
Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J. Clin. Psychopharmacol. 22(3), 257-262 (2002).
-
(2002)
J. Clin. Psychopharmacol
, vol.22
, Issue.3
, pp. 257-262
-
-
Kobak, K.A.1
Greist, J.H.2
Jefferson, J.W.3
Katzelnick, D.J.4
-
70
-
-
33847038810
-
Fluvoxamine treatment of generalized social anxiety disorder in Japan: A randomized double-blind, placebo-controlled study
-
Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 10(2), 263-267 (2007).
-
(2007)
Int. J. Neuropsychopharmacol
, vol.10
, Issue.2
, pp. 263-267
-
-
Asakura, S.1
Tajima, O.2
Koyama, T.3
-
71
-
-
1642307074
-
Fluvoxamine- controlled release formulation for the treatment of generalized social anxiety disorder
-
Davidson J, Yaryura-Tobias J, DuPont R et al. Fluvoxamine- controlled release formulation for the treatment of generalized social anxiety disorder. J. Clin. Psychopharmacol. 24(2), 118-125 (2004).
-
(2004)
J. Clin. Psychopharmacol
, vol.24
, Issue.2
, pp. 118-125
-
-
Davidson, J.1
Yaryura-Tobias, J.2
DuPont, R.3
-
72
-
-
0032894805
-
Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebocontrolled study
-
Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebocontrolled study. Am. J. Psychiatry 156(5), 756-760 (1999).
-
(1999)
Am. J. Psychiatry
, vol.156
, Issue.5
, pp. 756-760
-
-
Stein, M.B.1
Fyer, A.J.2
Davidson, J.R.3
Pollack, M.H.4
Wiita, B.5
-
73
-
-
0028340187
-
Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine
-
van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl.) 115(1-2), 128-134 (1994).
-
(1994)
Psychopharmacology (Berl.)
, vol.115
, Issue.1-2
, pp. 128-134
-
-
van Vliet, I.M.1
den Boer, J.A.2
Westenberg, H.G.3
-
74
-
-
1642539050
-
A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder
-
Westenberg HGM, Stein DJ, Yang H, Li D, Barbato LM. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J. Clin. Psychopharmacol. 24(1), 49-55 (2005).
-
(2005)
J. Clin. Psychopharmacol
, vol.24
, Issue.1
, pp. 49-55
-
-
Westenberg, H.G.M.1
Stein, D.J.2
Yang, H.3
Li, D.4
Barbato, L.M.5
-
75
-
-
0032867886
-
Paroxetine in social social anxiety disorder: A randomised placebo-controlled study
-
Allgulander C. Paroxetine in social social anxiety disorder: a randomised placebo-controlled study. Acta Psychiatr. Scand. 100(3), 193-198 (1999).
-
(1999)
Acta Psychiatr. Scand
, vol.100
, Issue.3
, pp. 193-198
-
-
Allgulander, C.1
-
76
-
-
0032773913
-
Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study
-
Baldwin D, Bobes J, Stein DJ, Scharwaechter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Br. J. Psychiatry 175, 120-126 (1999).
-
(1999)
Br. J. Psychiatry
, vol.175
, pp. 120-126
-
-
Baldwin, D.1
Bobes, J.2
Stein, D.J.3
Scharwaechter, I.4
Faure, M.5
-
77
-
-
0036152363
-
A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder
-
Liebowitz MR, Stein MB, Tancer M et al. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J. Clin. Psychiatry 63(1), 66-74 (2002).
-
(2002)
J. Clin. Psychiatry
, vol.63
, Issue.1
, pp. 66-74
-
-
Liebowitz, M.R.1
Stein, M.B.2
Tancer, M.3
-
78
-
-
1842866930
-
Controlled-release paroxetine in the treatment of patients with social anxiety disorder
-
Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J. Clin. Psychiatry 65(2), 222-229 (2004).
-
(2004)
J. Clin. Psychiatry
, vol.65
, Issue.2
, pp. 222-229
-
-
Lepola, U.1
Bergtholdt, B.2
St Lambert, J.3
Davy, K.L.4
Ruggiero, L.5
-
79
-
-
0035665364
-
Paroxetine for social anxiety and alcohol use in dual-diagnosed patients
-
Randall CL, Johnson MR, Thevos AK et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress. Anxiety 14(4), 255-262 (2001).
-
(2001)
Depress. Anxiety
, vol.14
, Issue.4
, pp. 255-262
-
-
Randall, C.L.1
Johnson, M.R.2
Thevos, A.K.3
-
80
-
-
0030014796
-
Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation
-
Stein MB, Chartier MJ, Hazen AL et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J. Clin. Psychopharmacol. 16(3), 218-222 (1996).
-
(1996)
J. Clin. Psychopharmacol
, vol.16
, Issue.3
, pp. 218-222
-
-
Stein, M.B.1
Chartier, M.J.2
Hazen, A.L.3
-
81
-
-
0001229940
-
Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder
-
S
-
Kumar R, Pitts C, Carpenter D. Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder. Eur. Neuropsychopharmacol. 9(Suppl. 5), S312 (1999).
-
(1999)
Eur. Neuropsychopharmacol
, vol.9
, Issue.SUPPL. 5
, pp. 312
-
-
Kumar, R.1
Pitts, C.2
Carpenter, D.3
-
82
-
-
0032569245
-
Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
-
Stein MB, Liebowitz MR, Lydiard RB et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. J. Am. Med. Assoc. 280(8), 708-713 (1998).
-
(1998)
J. Am. Med. Assoc
, vol.280
, Issue.8
, pp. 708-713
-
-
Stein, M.B.1
Liebowitz, M.R.2
Lydiard, R.B.3
-
83
-
-
0042306153
-
Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study
-
Liebowitz MR, DeMartinis N, Weihs KL et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J. Clin. Psychiatry 64(7), 785-792 (2003).
-
(2003)
J. Clin. Psychiatry
, vol.64
, Issue.7
, pp. 785-792
-
-
Liebowitz, M.R.1
DeMartinis, N.2
Weihs, K.L.3
-
84
-
-
0035146313
-
Sertraline treatment of generalised social phobia: A 20-week, double-blind, placebo-controlled study
-
Van Ameringen MA, Lane RM, Walker JR et al. Sertraline treatment of generalised social phobia: a 20-week, double-blind, placebo-controlled study. Am. J. Psychiatry 158(2), 275-281 (2001).
-
(2001)
Am. J. Psychiatry
, vol.158
, Issue.2
, pp. 275-281
-
-
Van Ameringen, M.A.1
Lane, R.M.2
Walker, J.R.3
-
85
-
-
13244255707
-
Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder
-
Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry 62(2), 190-198 (2005).
-
(2005)
Arch. Gen. Psychiatry
, vol.62
, Issue.2
, pp. 190-198
-
-
Liebowitz, M.R.1
Gelenberg, A.J.2
Munjack, D.3
-
86
-
-
4644343737
-
A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder
-
Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J. Clin. Psychopharmacol. 24(5), 488-496 (2004).
-
(2004)
J. Clin. Psychopharmacol
, vol.24
, Issue.5
, pp. 488-496
-
-
Rickels, K.1
Mangano, R.2
Khan, A.3
-
87
-
-
0030982241
-
Clinical effects of busiprone in social phobia: A double-blind placebo-controlled study
-
van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of busiprone in social phobia: a double-blind placebo-controlled study. J. Clin. Psychiatry 58(4), 164-168 (1997).
-
(1997)
J. Clin. Psychiatry
, vol.58
, Issue.4
, pp. 164-168
-
-
van Vliet, I.M.1
den Boer, J.A.2
Westenberg, H.G.3
Pian, K.L.4
-
88
-
-
0031706618
-
Discontinuation of clonazepam in the treatment of social phobia
-
Connor KM, Davidson JR, Potts NL et al. Discontinuation of clonazepam in the treatment of social phobia. J. Clin. Psychopharmacol. 18(5), 373-378 (1998).
-
(1998)
J. Clin. Psychopharmacol
, vol.18
, Issue.5
, pp. 373-378
-
-
Connor, K.M.1
Davidson, J.R.2
Potts, N.L.3
-
89
-
-
0027764363
-
Treatment of social phobia with clonazepan and placebo
-
Davidson JR, Potts N, Richichi E et al. Treatment of social phobia with clonazepan and placebo. J. Clin. Psychopharmacol. 13(6), 423-428 (1993).
-
(1993)
J. Clin. Psychopharmacol
, vol.13
, Issue.6
, pp. 423-428
-
-
Davidson, J.R.1
Potts, N.2
Richichi, E.3
-
90
-
-
25844473118
-
Levetiracetam in social phobia: A placebo controlled pilot study
-
Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J. Psychopharmacol. (Oxford) 19(5), 551-553 (2005).
-
(2005)
J. Psychopharmacol. (Oxford)
, vol.19
, Issue.5
, pp. 551-553
-
-
Zhang, W.1
Connor, K.M.2
Davidson, J.R.3
-
91
-
-
12144285831
-
Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study
-
Pande A, Feltner D, Jefferson J et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J. Clin. Psychopharmacol. 24(2), 141-149 (2004).
-
(2004)
J. Clin. Psychopharmacol
, vol.24
, Issue.2
, pp. 141-149
-
-
Pande, A.1
Feltner, D.2
Jefferson, J.3
-
92
-
-
27544443726
-
A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder
-
Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry 66(10), 1270-1278 (2005).
-
(2005)
J. Clin. Psychiatry
, vol.66
, Issue.10
, pp. 1270-1278
-
-
Montgomery, S.A.1
Nil, R.2
Durr-Pal, N.3
Loft, H.4
Boulenger, J.P.5
-
93
-
-
0036895568
-
Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study
-
Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch. Gen. Psychiatry 59(12), 1111-1118 (2002).
-
(2002)
Arch. Gen. Psychiatry
, vol.59
, Issue.12
, pp. 1111-1118
-
-
Stein, D.J.1
Versiani, M.2
Hair, T.3
Kumar, R.4
-
94
-
-
0020664319
-
Effect on pindolol on stress-related disturbances of musical performance: Preliminary communication
-
James IM, Burgoyne W, Savage IT. Effect on pindolol on stress-related disturbances of musical performance: preliminary communication. J. R. Soc. Med. 76(3), 194-196 (1983).
-
(1983)
J. R. Soc. Med
, vol.76
, Issue.3
, pp. 194-196
-
-
James, I.M.1
Burgoyne, W.2
Savage, I.T.3
-
95
-
-
4344610707
-
Efficacy and tolerability of controlled-release paroxetine
-
Golden R. Efficacy and tolerability of controlled-release paroxetine. Psychopharmacol. Bull. 37(Suppl. 1), 176-186 (2003).
-
(2003)
Psychopharmacol. Bull
, vol.37
, Issue.SUPPL. 1
, pp. 176-186
-
-
Golden, R.1
-
96
-
-
0030948067
-
Double-blind placebo controlled trial with bromazepam in social phobia
-
Versiani M, Nardi AE, Figueira I, Mendlowicz M, Marques C. Double-blind placebo controlled trial with bromazepam in social phobia. J. Bras. Psiquiatr. 46(3), 167-171 (1997).
-
(1997)
J. Bras. Psiquiatr
, vol.46
, Issue.3
, pp. 167-171
-
-
Versiani, M.1
Nardi, A.E.2
Figueira, I.3
Mendlowicz, M.4
Marques, C.5
-
97
-
-
0021276677
-
Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice
-
Allsopp LF, Cooper GL, Poole PH. Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Curr. Med. Res. Opin. 9(1), 64-70 (1984).
-
(1984)
Curr. Med. Res. Opin
, vol.9
, Issue.1
, pp. 64-70
-
-
Allsopp, L.F.1
Cooper, G.L.2
Poole, P.H.3
-
98
-
-
4344645041
-
ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder
-
Montgomery SA, Lecrubier Y, Baldwin D et al. ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. Eur. Neuropsychopharmacol. 14, 425-433 (2004).
-
(2004)
Eur. Neuropsychopharmacol
, vol.14
, pp. 425-433
-
-
Montgomery, S.A.1
Lecrubier, Y.2
Baldwin, D.3
-
99
-
-
2442567884
-
How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia
-
Lincoln TM, Rief W. How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia. J. Anxiety Disord. 18(4), 515-529 (2004).
-
(2004)
J. Anxiety Disord
, vol.18
, Issue.4
, pp. 515-529
-
-
Lincoln, T.M.1
Rief, W.2
-
100
-
-
0037664376
-
-
Schneier FR, Blanco C, Campeas R et al. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress. Anxiety 17(4), 191-196 (2003). •• A thorough and novel synthesis of randomized controlled trials of pharmacotherapy for SAD. Results of a power analysis revealed that comparisons are insufficiently powered in many cases to detect a statistically significant difference in efficacy between medications. Authors conclude on the basis of a cumulative meta-analysis that sufficient evidence exists to claim with confidence that selective serotonin reuptake inhibitors (SSRIs) and brofaromine are effective in treating this disorder.
-
Schneier FR, Blanco C, Campeas R et al. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress. Anxiety 17(4), 191-196 (2003). •• A thorough and novel synthesis of randomized controlled trials of pharmacotherapy for SAD. Results of a power analysis revealed that comparisons are insufficiently powered in many cases to detect a statistically significant difference in efficacy between medications. Authors conclude on the basis of a cumulative meta-analysis that sufficient evidence exists to claim with confidence that selective serotonin reuptake inhibitors (SSRIs) and brofaromine are effective in treating this disorder.
-
-
-
-
101
-
-
0034805127
-
Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study
-
Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am. J. Psychiatry 158(10), 1725-1727 (2001).
-
(2001)
Am. J. Psychiatry
, vol.158
, Issue.10
, pp. 1725-1727
-
-
Stein, M.B.1
Sareen, J.2
Hami, S.3
Chao, J.4
-
102
-
-
39549114184
-
-
Nemeroff CB, Entsuah R, Benattia I et al. Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs. Biol. Psychiatry PMID: 17888885 (2007) (Epub ahead of print). • This study represents the largest comparison of the relative efficacy of antidepressants ever undertaken, presenting the results of a systematic comparison of the efficacy of 8 weeks of treatment with venlafaxine versus individual SSRI agents in 8744 patients from Wyeth sponsored trials of depression. The finding that fluoxetine was the only SSRI which was more effective than venlafaxine was used by the authors to temper the significance of the reported 5.9% advantage of venlafaxine versus SSRIs in remission rates, as over half of the patients treated with SSRIs were receiving fluoxetine.
-
Nemeroff CB, Entsuah R, Benattia I et al. Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs. Biol. Psychiatry PMID: 17888885 (2007) (Epub ahead of print). • This study represents the largest comparison of the relative efficacy of antidepressants ever undertaken, presenting the results of a systematic comparison of the efficacy of 8 weeks of treatment with venlafaxine versus individual SSRI agents in 8744 patients from Wyeth sponsored trials of depression. The finding that fluoxetine was the only SSRI which was more effective than venlafaxine was used by the authors to temper the significance of the reported 5.9% advantage of venlafaxine versus SSRIs in remission rates, as over half of the patients treated with SSRIs were receiving fluoxetine.
-
-
-
-
103
-
-
0031464343
-
Social phobia: Long-term treatment outcome and prediction of response - a moclobemide study
-
Versiani M, Amrein R, Montgomery S. Social phobia: long-term treatment outcome and prediction of response - a moclobemide study. Int. Clin. Psychopharmacol. 12(5), 239-254 (1997).
-
(1997)
Int. Clin. Psychopharmacol
, vol.12
, Issue.5
, pp. 239-254
-
-
Versiani, M.1
Amrein, R.2
Montgomery, S.3
-
104
-
-
39549090299
-
Cognitive behavior therapy versus moclobemide in social phobia
-
Presented at:, Jerusalem, Israel, 16-21 November
-
Oosterbaan D, van Balkom A, Spinhoven, van Dyk R. Cognitive behavior therapy versus moclobemide in social phobia. Presented at: WPA Thematic Conference. Jerusalem, Israel, 16-21 November (1997).
-
(1997)
WPA Thematic Conference
-
-
Oosterbaan, D.1
van Balkom, A.2
Spinhoven3
van Dyk, R.4
-
105
-
-
0029562945
-
Personality traits in social phobia
-
Fahlen T. Personality traits in social phobia. J. Clin. Psychiatry 56(12), 569-573 (1995).
-
(1995)
J. Clin. Psychiatry
, vol.56
, Issue.12
, pp. 569-573
-
-
Fahlen, T.1
-
106
-
-
7044274308
-
Co-occurence of 12-month mood and anxiety disorders and personality disorders in the US: Results from the national epidemiologic survey on alcohol and related conditions
-
Grant BF, Hasin DF, Stinson FS. Co-occurence of 12-month mood and anxiety disorders and personality disorders in the US: results from the national epidemiologic survey on alcohol and related conditions. J. Psychiatr. Res. (39), 1-9 (2005).
-
(2005)
J. Psychiatr. Res
, vol.39
, pp. 1-9
-
-
Grant, B.F.1
Hasin, D.F.2
Stinson, F.S.3
-
107
-
-
7244254160
-
Associations in the course of personality disorders and Axis I disorders over time
-
Shea MT, Stout RL, Yen S et al. Associations in the course of personality disorders and Axis I disorders over time. J. Abnorm. Psychol. 113(4), 499-508 (2004).
-
(2004)
J. Abnorm. Psychol
, vol.113
, Issue.4
, pp. 499-508
-
-
Shea, M.T.1
Stout, R.L.2
Yen, S.3
-
108
-
-
33751537253
-
An epidemiologic perspective on social anxiety disorder
-
Stein MB. An epidemiologic perspective on social anxiety disorder. J. Clin. Psychiatry 67(Suppl. 12), 3-8 (2006).
-
(2006)
J. Clin. Psychiatry
, vol.67
, Issue.SUPPL. 12
, pp. 3-8
-
-
Stein, M.B.1
-
109
-
-
0035701239
-
Taijin kyofusho: A form of social anxiety disorder that repsonds to serotonin reuptake inhibitors?
-
Matsunaga H, Kiriike N, Matsui T, Iwasaki Y, Stein DJ. Taijin kyofusho: a form of social anxiety disorder that repsonds to serotonin reuptake inhibitors? Int. J. Neuropsychopharmacol. 4(3), 231-237 (2001).
-
(2001)
Int. J. Neuropsychopharmacol
, vol.4
, Issue.3
, pp. 231-237
-
-
Matsunaga, H.1
Kiriike, N.2
Matsui, T.3
Iwasaki, Y.4
Stein, D.J.5
-
110
-
-
0031940749
-
Is olfactory reference syndrome on the obsessive-compulsive spectrum? Two cases and a discussion
-
Stein DJ, Le Roux L, Bouwer C, Van Heerden B. Is olfactory reference syndrome on the obsessive-compulsive spectrum? Two cases and a discussion. J. Neuropsychiatry Clin. Neurosci. 10(1), 96-99 (1998).
-
(1998)
J. Neuropsychiatry Clin. Neurosci
, vol.10
, Issue.1
, pp. 96-99
-
-
Stein, D.J.1
Le Roux, L.2
Bouwer, C.3
Van Heerden, B.4
-
111
-
-
0035171845
-
Pharmacotherapy of social anxiety disorder at the turn of the millennium
-
Van Ameringen M, Mancini C. Pharmacotherapy of social anxiety disorder at the turn of the millennium. Psychiatr. Clin. North Am. 24(4), 783-803 (2001).
-
(2001)
Psychiatr. Clin. North Am
, vol.24
, Issue.4
, pp. 783-803
-
-
Van Ameringen, M.1
Mancini, C.2
-
112
-
-
16544366906
-
-
Zimmerman M, Chelminski I, Young D. On the threshold of disorder: a study of the impact of the DSM-IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. J. Clin. Psychiatry 65(10, 1400-1405 (2004, • A study assessing the impact of the requirement of clinical significance in diagnosing depression and anxiety disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria. Based on a sample of outpatients participating in the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project, the diagnosis of lifetime SAD depended to a greater extent on fulfillment of the criteria of clinical significance than either major depressive disorder or post-traumatic stress disorder
-
Zimmerman M, Chelminski I, Young D. On the threshold of disorder: a study of the impact of the DSM-IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. J. Clin. Psychiatry 65(10), 1400-1405 (2004). • A study assessing the impact of the requirement of clinical significance in diagnosing depression and anxiety disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria. Based on a sample of outpatients participating in the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project, the diagnosis of lifetime SAD depended to a greater extent on fulfillment of the criteria of clinical significance than either major depressive disorder or post-traumatic stress disorder.
-
-
-
-
113
-
-
0015583292
-
Controlled evaluation of intravenous drugs in the specific desensitization of phobias
-
Silverstone JT, Salkind MR. Controlled evaluation of intravenous drugs in the specific desensitization of phobias. Can. Psychiatr. Assoc. J. 18(1), 47-53 (1973).
-
(1973)
Can. Psychiatr. Assoc. J
, vol.18
, Issue.1
, pp. 47-53
-
-
Silverstone, J.T.1
Salkind, M.R.2
-
114
-
-
0015579378
-
Behaviour therapy versus drug therapy in the treatment of phobic neurosis
-
Solyom L, Heseltine GF, McClure DJ et al. Behaviour therapy versus drug therapy in the treatment of phobic neurosis. Can. Psychiatr. Assoc. J. 18(1), 25-32 (1973).
-
(1973)
Can. Psychiatr. Assoc. J
, vol.18
, Issue.1
, pp. 25-32
-
-
Solyom, L.1
Heseltine, G.F.2
McClure, D.J.3
-
115
-
-
4444260376
-
Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders
-
Kuzma JM, Black DW. Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders. Curr. Psychiatry Rep. 6(4), 268-273 (2004).
-
(2004)
Curr. Psychiatry Rep
, vol.6
, Issue.4
, pp. 268-273
-
-
Kuzma, J.M.1
Black, D.W.2
-
116
-
-
0030742003
-
-
Bailar JC 3rd. The promise and problems of meta-analysis. N. Engl. J. Med. 337(8), 559-561 (1999).
-
Bailar JC 3rd. The promise and problems of meta-analysis. N. Engl. J. Med. 337(8), 559-561 (1999).
-
-
-
-
117
-
-
0037374008
-
Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses
-
Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br. Med. J. 326(7387), 472 (2003).
-
(2003)
Br. Med. J
, vol.326
, Issue.7387
, pp. 472
-
-
Song, F.1
Altman, D.G.2
Glenny, A.M.3
Deeks, J.J.4
-
118
-
-
0036906386
-
Efficacy of citalopram and moclobemide in patients with social phobia: Some preliminary findings
-
Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum. Psychopharmacol. 17(8), 401-405 (2002).
-
(2002)
Hum. Psychopharmacol
, vol.17
, Issue.8
, pp. 401-405
-
-
Atmaca, M.1
Kuloglu, M.2
Tezcan, E.3
Unal, A.4
-
119
-
-
39549121604
-
Social phobia
-
American Psychiatric Publishing Inc, Arlington, VA, USA
-
Schneier FR, Luterek JA, Heimberg RG, Leonardo E, Stein DJ. Social phobia. In: Clinical Manual of Anxiety Disorders. American Psychiatric Publishing Inc., Arlington, VA, USA, 63-86 (2004).
-
(2004)
Clinical Manual of Anxiety Disorders
, pp. 63-86
-
-
Schneier, F.R.1
Luterek, J.A.2
Heimberg, R.G.3
Leonardo, E.4
Stein, D.J.5
-
120
-
-
0032794768
-
Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor nonresponders
-
Altamura A, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor nonresponders. Int. Clin. Psychopharmacol. 14(4), 239-245 (1999).
-
(1999)
Int. Clin. Psychopharmacol
, vol.14
, Issue.4
, pp. 239-245
-
-
Altamura, A.1
Pioli, R.2
Vitto, M.3
Mannu, P.4
-
121
-
-
0042326758
-
Phenelzine efficacy in refractory social anxiety disorder: A case series
-
Aarre TF. Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord. J. Psychiatry 57(4), 313-315 (2003).
-
(2003)
Nord. J. Psychiatry
, vol.57
, Issue.4
, pp. 313-315
-
-
Aarre, T.F.1
-
122
-
-
33846527318
-
-
Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr. 12(1), 51-61 (2007). • The NMDA agonist d-cycloserine is argued on theoretical grounds and on the basis of animal research to faciliate the extinction learning component of cognitive-behavioral therapy in treating anxiety disorders. The favourable side-effect profile and lack of evidence of affect modulation of low isolated doses of this agent suggest that it may bypass the context-dependence learning thought to account for the dissapointing performance of studies combining medication and psychotherapy in treating this class of disorders.
-
Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr. 12(1), 51-61 (2007). • The NMDA agonist d-cycloserine is argued on theoretical grounds and on the basis of animal research to faciliate the extinction learning component of cognitive-behavioral therapy in treating anxiety disorders. The favourable side-effect profile and lack of evidence of affect modulation of low isolated doses of this agent suggest that it may bypass the context-dependence learning thought to account for the dissapointing performance of studies combining medication and psychotherapy in treating this class of disorders.
-
-
-
-
123
-
-
0026069816
-
Cognitive-behavioural and pharmacological treatments of social phobia: A controlled study
-
Gelernter CS, Uhde TW, Cimbolic P et al. Cognitive-behavioural and pharmacological treatments of social phobia: a controlled study. Arch. Gen. Psychiatry 48(10), 938-945 (1991).
-
(1991)
Arch. Gen. Psychiatry
, vol.48
, Issue.10
, pp. 938-945
-
-
Gelernter, C.S.1
Uhde, T.W.2
Cimbolic, P.3
-
124
-
-
0018762593
-
Flooding with brevital in the treatment of agoraphobia - countereffective?
-
Chambless D, Foa E, Groves G, Goldstein A. Flooding with brevital in the treatment of agoraphobia - countereffective? Behav. Res. Ther. 17, 243-251 (1979).
-
(1979)
Behav. Res. Ther
, vol.17
, pp. 243-251
-
-
Chambless, D.1
Foa, E.2
Groves, G.3
Goldstein, A.4
-
125
-
-
0025022289
-
Behavior therapy and benzodiazepines: Allies or antagonists?
-
Wardle J. Behavior therapy and benzodiazepines: allies or antagonists? Br. J. Psychiatry 156, 163-168 (1990).
-
(1990)
Br. J. Psychiatry
, vol.156
, pp. 163-168
-
-
Wardle, J.1
-
126
-
-
33750283860
-
Defining response and remission in anxiety disorders. Towards an integrated approach
-
Bandelow B. Defining response and remission in anxiety disorders. Towards an integrated approach. CNS Spectr. 11(10 Suppl. 12), 21-28 (2006).
-
(2006)
CNS Spectr
, vol.11
, Issue.10 SUPPL. 12
, pp. 21-28
-
-
Bandelow, B.1
-
127
-
-
39549116419
-
-
London
-
Kings College London. www.iop.kcl.ac.uk/IoP/ccdan/qrs.htm
-
-
-
College, K.1
-
137
-
-
39549107475
-
-
GSK. fMRI study comparing BOLD activation patterns using GW679769 in subjects with social anxiety disorder. http://clinicaltrials.gov/ct/show/ NCT00332046 (Accessed September 2007)
-
GSK. fMRI study comparing BOLD activation patterns using GW679769 in subjects with social anxiety disorder. http://clinicaltrials.gov/ct/show/ NCT00332046 (Accessed September 2007)
-
-
-
|